EC
APLS

EcoR1 Capital’s Apellis Pharmaceuticals APLS Stock Holding History

EcoR1 Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,447,156
Closed -$78M – 32
2025
Q3 		$78M Sell
3,447,156
-8,448,652
-71% -$197M 3.74% 9
2025
Q2 		$206M Hold
11,895,808
– – 12.19% 2
2025
Q1 		$260M Buy
11,895,808
+4,965
+0% +$137K 15.43% 1
2024
Q4 		$379M Hold
11,890,843
– – 14.35% 1
2024
Q3 		$343M Buy
11,890,843
+283,418
+2% +$10.5M 11.74% 1
2024
Q2 		$445M Buy
11,607,425
+250,000
+2% +$11.3M 13.62% 1
2024
Q1 		$668M Buy
11,357,425
+184,357
+2% +$11.8M 16.89% 1
2023
Q4 		$669M Buy
11,173,068
+273,209
+3% +$13.9M 17.37% 1
2023
Q3 		$415M Buy
10,899,859
+5,448,212
+100% +$239M 13.99% 2
2023
Q2 		$497M Hold
5,451,647
– – 12.17% 2
2023
Q1 		$360M Buy
5,451,647
+268,216
+5% +$15.5M 11.58% 3
2022
Q4 		$268M Hold
5,183,431
– – 8.16% 3
2022
Q3 		$354M Hold
5,183,431
– – 10.45% 2
2022
Q2 		$234M Hold
5,183,431
– – 8.09% 2
2022
Q1 		$263M Buy
5,183,431
+1,149,549
+28% +$50.7M 8.24% 2
2021
Q4 		$191M Buy
+4,033,882
New +$159M 6.08% 5
2018
Q2 		– Sell
-1,056,348
Closed -$23.4M – 36
2018
Q1 		$23.4M Sell
1,056,348
-88,210
-8% -$1.73M 2.34% 12
2017
Q4 		$24.8M Buy
+1,144,558
New +$16.8M 2.8% 11

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

EcoR1 Capital's APLS Position: Q4 2025 in Review

EcoR1 Capital sold out of Apellis Pharmaceuticals (APLS) in Q4 2025, closing a stake of 3,447,156 shares — an estimated $78M sold.

EcoR1 Capital first reported a position in APLS in Q4 2017 and held it in 18 quarters. The position peaked at $669M in Q4 2023. 279 funds tracked by Wall St. Rank hold APLS as of Q4 2025.

  • EcoR1 Capital reported no remaining Apellis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • EcoR1 Capital sold 3,447,156 Apellis Pharmaceuticals shares in Q4 2025, an estimated $78M.
  • EcoR1 Capital first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 18 quarters.
  • EcoR1 Capital's Apellis Pharmaceuticals position peaked at $669M in Q4 2023.
  • 279 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2025.

Based on EcoR1 Capital's 13F filing for Q4 2025, filed 17 Feb 2026.